Balgis Elhag Ibrahim Tager, Salah Eldin G. Elzaki, Ahmed Abdula Agabeldour, Hussain Gadelkarim Ahmed
{"title":"KRAS and P53 Gene Mutation Patterns Linked to Colorectal Cancer in Sudan","authors":"Balgis Elhag Ibrahim Tager, Salah Eldin G. Elzaki, Ahmed Abdula Agabeldour, Hussain Gadelkarim Ahmed","doi":"10.36348/sjm.2024.v09i02.004","DOIUrl":null,"url":null,"abstract":"Background: Molecular pathogenesis of CRC represents a major target for understanding and controlling of the disease in the Sudan. Therefore, the present study aimed to explore the clinicopathological pattern of CRC in the Sudan with specific emphases in the role KRAS and P53 genes mutations. Methodology: This study was carried out in El-Obeid, North Kordofan state, Sudan, using CRC samples from patients who presented to the Al-Obeid teaching hospital between 2017 and 2022 and had a biopsy for histopathological diagnosis. This series featured everyone who has CRC. Results: The most prevalent CRC subtype is adenocarcinoma, which is followed by mucinous adenocarcinoma and metastatic adenocarcinoma, which constitute 74%, 20%, and 6%, respectively. KRAS mutation was found in 40% patients 48% males and 33.3% females). P53 mutation was found in 46% individuals 43.5% men and 48% females. Positive correlations between KRAS and P53 were found in 26% cases, while negative correlations were found in 40% cases. Conclusion: Many CRC patients in Sudan present at advanced stages of the illness and at a younger age, necessitating early screening measures. CRC patients have been discovered to have KRAS, P53, or both mutations. As a result, precise preventative and therapeutic methods are considered essential.","PeriodicalId":510088,"journal":{"name":"Saudi Journal of Medicine","volume":"353 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36348/sjm.2024.v09i02.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Molecular pathogenesis of CRC represents a major target for understanding and controlling of the disease in the Sudan. Therefore, the present study aimed to explore the clinicopathological pattern of CRC in the Sudan with specific emphases in the role KRAS and P53 genes mutations. Methodology: This study was carried out in El-Obeid, North Kordofan state, Sudan, using CRC samples from patients who presented to the Al-Obeid teaching hospital between 2017 and 2022 and had a biopsy for histopathological diagnosis. This series featured everyone who has CRC. Results: The most prevalent CRC subtype is adenocarcinoma, which is followed by mucinous adenocarcinoma and metastatic adenocarcinoma, which constitute 74%, 20%, and 6%, respectively. KRAS mutation was found in 40% patients 48% males and 33.3% females). P53 mutation was found in 46% individuals 43.5% men and 48% females. Positive correlations between KRAS and P53 were found in 26% cases, while negative correlations were found in 40% cases. Conclusion: Many CRC patients in Sudan present at advanced stages of the illness and at a younger age, necessitating early screening measures. CRC patients have been discovered to have KRAS, P53, or both mutations. As a result, precise preventative and therapeutic methods are considered essential.